开云app官网登录入口网页版-官方正版

#Nintedanib#

24篇内容 | 1518人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361798, encodeId=465e1361e9857, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Clin Oncol：晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效, objectType=article, longId=301250, objectId=210e30125037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210e30125037, replyNumber=0, likeNumber=63, createdTime=2022-03-22, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210e30125037, moduleTitle=Clin Oncol：晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=210e30125037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361797, encodeId=b5a21361e9714, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Nintedanib治疗系统性硬化症相关性间质性肺病：已获得CHMP的积极评价, objectType=article, longId=189088, objectId=39b718908848, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b718908848, replyNumber=0, likeNumber=69, createdTime=2020-03-03, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b718908848, moduleTitle=Nintedanib治疗系统性硬化症相关性间质性肺病：已获得CHMP的积极评价, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=39b718908848)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361796, encodeId=5a841361e9681, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Brit J Cancer：Nintedanib：肝内胆管癌的新福音——尼达尼布！, objectType=article, longId=187798, objectId=7c9018e79870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9018e79870, replyNumber=0, likeNumber=75, createdTime=2020-02-12, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9018e79870, moduleTitle=Brit J Cancer：Nintedanib：肝内胆管癌的新福音——尼达尼布！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7c9018e79870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361795, encodeId=b7591361e955e, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降, objectType=article, longId=183715, objectId=fe2f183e1514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2f183e1514, replyNumber=0, likeNumber=72, createdTime=2019-11-29, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2f183e1514, moduleTitle=加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe2f183e1514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361794, encodeId=b0bc1361e9482, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM：nintedanib可以减缓间质性肺病患者肺功能的下降, objectType=article, longId=180874, objectId=d8701808e4d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8701808e4d2, replyNumber=0, likeNumber=66, createdTime=2019-10-12, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8701808e4d2, moduleTitle=NEJM：nintedanib可以减缓间质性肺病患者肺功能的下降, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d8701808e4d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361793, encodeId=44171361e9302, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=2019年ERS：Nintedanib减慢纤维化间质性肺病的进展, objectType=article, longId=180637, objectId=7ff718063eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ff718063eac, replyNumber=0, likeNumber=78, createdTime=2019-10-09, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ff718063eac, moduleTitle=2019年ERS：Nintedanib减慢纤维化间质性肺病的进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7ff718063eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361792, encodeId=3dfd1361e9295, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病, objectType=article, longId=179152, objectId=816f1e9152ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=816f1e9152ed, replyNumber=0, likeNumber=80, createdTime=2019-09-10, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=816f1e9152ed, moduleTitle=FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=816f1e9152ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361791, encodeId=226b1361e91ad, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM：Nintedanib治疗系统性硬化性间质性肺病, objectType=article, longId=174366, objectId=d34f1e436665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d34f1e436665, replyNumber=0, likeNumber=83, createdTime=2019-06-29, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d34f1e436665, moduleTitle=NEJM：Nintedanib治疗系统性硬化性间质性肺病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d34f1e436665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361790, encodeId=f2411361e901d, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM：Nintedanib系统性硬化相关的肺间质疾病的效果, objectType=article, longId=168676, objectId=cd361686e684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd361686e684, replyNumber=0, likeNumber=75, createdTime=2019-06-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd361686e684, moduleTitle=NEJM：Nintedanib系统性硬化相关的肺间质疾病的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cd361686e684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361789, encodeId=99c21361e899d, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=ANN ONCOL：Nintedanib治疗难治性转移性结直肠癌, objectType=article, longId=149951, objectId=509f149951c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=509f149951c3, replyNumber=0, likeNumber=72, createdTime=2018-09-30, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=509f149951c3, moduleTitle=ANN ONCOL：Nintedanib治疗难治性转移性结直肠癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=509f149951c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361788, encodeId=08971361e882f, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=nintedanib对恶性胸膜间皮瘤的有效性, objectType=article, longId=138660, objectId=4ae8138660ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ae8138660ec, replyNumber=0, likeNumber=60, createdTime=2018-05-22, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ae8138660ec, moduleTitle=nintedanib对恶性胸膜间皮瘤的有效性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ae8138660ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361787, encodeId=53a71361e8720, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=BI：Ofev®（nintedanib，尼达尼布）治疗特发性肺纤维化表现出持续长期疗效, objectType=article, longId=122647, objectId=9b3f12264ea6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3f12264ea6, replyNumber=0, likeNumber=68, createdTime=2017-12-09, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3f12264ea6, moduleTitle=BI：Ofev®（nintedanib，尼达尼布）治疗特发性肺纤维化表现出持续长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9b3f12264ea6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361786, encodeId=a7451361e8614, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位, objectType=article, longId=77494, objectId=d3b3e749422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b3e749422, replyNumber=0, likeNumber=52, createdTime=2016-09-16, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b3e749422, moduleTitle=勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d3b3e749422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361785, encodeId=12ef1361e85b0, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Lancet Oncol：标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著, objectType=article, longId=58865, objectId=72f55886548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72f55886548, replyNumber=0, likeNumber=71, createdTime=2015-11-18, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72f55886548, moduleTitle=Lancet Oncol：标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=72f55886548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361784, encodeId=8d8a1361e8484, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Respir Res：尼达尼布（nintedanib）对特发性肺纤维化长期有效性且安全性良好（INPULSIS-ON试验）, objectType=article, longId=57387, objectId=bf105e387d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf105e387d9, replyNumber=0, likeNumber=87, createdTime=2015-10-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf105e387d9, moduleTitle=Respir Res：尼达尼布（nintedanib）对特发性肺纤维化长期有效性且安全性良好（INPULSIS-ON试验）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bf105e387d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361783, encodeId=86821361e83b1, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格启动抗癌药nintedanib结直肠癌全球III期研究, objectType=article, longId=41705, objectId=0fbd41e05ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fbd41e05ec, replyNumber=0, likeNumber=70, createdTime=2014-10-26, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fbd41e05ec, moduleTitle=勃林格启动抗癌药nintedanib结直肠癌全球III期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0fbd41e05ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361782, encodeId=176c1361e82a6, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=FDA同时批准罗氏Pirfenidone和BI的Nintedanib, objectType=article, longId=41401, objectId=a80241401dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a80241401dd, replyNumber=0, likeNumber=73, createdTime=2014-10-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a80241401dd, moduleTitle=FDA同时批准罗氏Pirfenidone和BI的Nintedanib, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a80241401dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361781, encodeId=76d51361e8183, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定, objectType=article, longId=38055, objectId=fc3c38055d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3c38055d3, replyNumber=0, likeNumber=64, createdTime=2014-07-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3c38055d3, moduleTitle=FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fc3c38055d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361780, encodeId=53bc1361e800d, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格, objectType=article, longId=38021, objectId=0ab338021cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab338021cd, replyNumber=0, likeNumber=90, createdTime=2014-07-20, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab338021cd, moduleTitle=勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0ab338021cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361779, encodeId=90131361e7985, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM：Nintedanib对特发性肺纤维化安全有效（INPULSIS试验）？, objectType=article, longId=36439, objectId=b4a0364396f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a0364396f, replyNumber=0, likeNumber=72, createdTime=2014-06-17, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a0364396f, moduleTitle=NEJM：Nintedanib对特发性肺纤维化安全有效（INPULSIS试验）？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b4a0364396f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Nintedanib

2020-05-29

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

Clin Oncol：晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效

2022-03-22

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

Nintedanib治疗系统性硬化症相关性间质性肺病：已获得CHMP的积极评价

2020-03-03

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

Brit J Cancer：Nintedanib：肝内胆管癌的新福音——尼达尼布！

2020-02-12

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降

2019-11-29

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

NEJM：nintedanib可以减缓间质性肺病患者肺功能的下降

2019-10-12

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

2019年ERS：Nintedanib减慢纤维化间质性肺病的进展

2019-10-09

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病

2019-09-10

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

NEJM：Nintedanib治疗系统性硬化性间质性肺病

2019-06-29

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

NEJM：Nintedanib系统性硬化相关的肺间质疾病的效果

2019-06-19

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

ANN ONCOL：Nintedanib治疗难治性转移性结直肠癌

2018-09-30

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

nintedanib对恶性胸膜间皮瘤的有效性

2018-05-22

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

BI：Ofev®（nintedanib，尼达尼布）治疗特发性肺纤维化表现出持续长期疗效

2017-12-09

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位

2016-09-16

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

Lancet Oncol：标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著

2015-11-18

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

Respir Res：尼达尼布（nintedanib）对特发性肺纤维化长期有效性且安全性良好（INPULSIS-ON试验）

2015-10-19

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

勃林格启动抗癌药nintedanib结直肠癌全球III期研究

2014-10-26

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

FDA同时批准罗氏Pirfenidone和BI的Nintedanib

2014-10-19

仁者大医 (审核中...)

前往app查看评论内容

#Nintedanib#

FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定

2014-07-23

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格

2014-07-20

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

NEJM：Nintedanib对特发性肺纤维化安全有效（INPULSIS试验）？

2014-06-17

科室
- - 订阅+
  - 更多科室
工具
服务